DDMODEL00000045: Clinical Rifampicin PKPD Model using the Multistate Tuberculosis Pharmacometric Model

  public model
Short description:
This is a clinical PKPD model for rifampicin monotherapy in pulmonary tuberculosis patients. The PKPD model includes a previously described PopPK model for rifampicin as well as the Multistate Tuberculosis Pharmacometric Model.
Original code
  • Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis
  • Robin J Svensson, Ulrika SH Simonsson
  • CPT: Pharmacometrics & Systems Pharmacology, 5/2016, Volume 5, Issue 5, pages: 264-273
  • Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
  • This is the first clinical implementation of the Multistate Tuberculosis Pharmacometric (MTP) model describing fast-, slow-, and nonmultiplying bacterial states of Mycobacterium tuberculosis. Colony forming unit data from 19 patients treated with rifampicin were analyzed. A previously developed rifampicin population pharmacokinetic (PK) model was linked to the MTP model previously developed using in vitro data. Drug effect was implemented as exposure-response relationships tested at several effect sites, both alone and in combination. All MTP model parameters were fixed to in vitro estimates except Bmax. Drug effect was described by an on/off effect inhibiting growth of fast-multiplying bacteria in addition to linear increase of the stimulation of the death rate of slow- and nonmultiplying bacteria with increasing drug exposure. Clinical trial simulations predicted well three retrospective clinical trials using the final model that confirmed the potential utility of the MTP model in antitubercular drug development.
Robin Svensson
Context of model development: Disease Progression model;
Model compliance with original publication: Yes;
Model implementation requiring submitter’s additional knowledge: No;
Modelling context description: This is a clinical PKPD model for rifampicin given in monotherapy for pulmonary tuberculosis patients. There are no clinical semi-mechanistic PKPD models for tuberculosis that links PK to PD. This model can be used for tuberculosis drug development.;
Modelling task in scope: estimation;
Nature of research: Early clinical development (Phases I and II);
Therapeutic/disease area: Anti-infectives;
Annotations are correct.
This model is not certified.
  • Model owner: Robin Svensson
  • Submitted: Dec 10, 2015 4:25:32 PM
  • Last Modified: May 25, 2016 1:16:33 PM
Revisions
  • Version: 8 public model Download this version
    • Submitted on: May 25, 2016 1:16:33 PM
    • Submitted by: Robin Svensson
    • With comment: Edited model metadata online.
  • Version: 4 public model Download this version
    • Submitted on: Dec 10, 2015 4:25:32 PM
    • Submitted by: Robin Svensson
    • With comment: Edited model metadata online.
 
Help